Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
Status:
Withdrawn
Trial end date:
2025-03-14
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies how well endocrine therapy works in treating patients with
HER2 negative, low risk breast cancer. Estrogen can cause the growth of breast cancer cells.
Endocrine therapies such as aromatase inhibitors and selective estrogen receptor modulators
may lessen the amount of estrogen made by the body.